佳士科技(300193.SZ):股東千鑫恆所持1290萬股將被拍賣
格隆匯 2 月 24日丨佳士科技(300193.SZ)公佈,公司於2020年11月24日發佈了《關於持股5%以上股東所持公司部分股份將被司法拍賣的提示性公吿》,公司持股5%以上股東深圳市千鑫恆投資發展有限公司(“千鑫恆”)因合同糾紛,其所持有的公司部分股份將被深圳市福田區人民法院公開拍賣。
近日,公司通過查詢“阿里拍賣•司法”網站(sf.taobao.com)獲悉千鑫恆持有的公司部分股份將被拍賣的進展情況,千鑫恆所持1290萬股將被拍賣,佔其所持股份比例25.75%,拍賣起始日2021年3月23日10時,拍賣到期日2021年3月24日10時。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.